Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 18 Observational 10 Expanded_access 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Neoplasms 11 Multiple Myeloma 10 Recurrence 9 Pancreatic Neoplasms 8 Prostatic Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neuroblastoma 6 Melanoma 6 Sarcoma 5 Ovarian Neoplasms 5 Leukemia, Myeloid, Acute 5 Hematologic Neoplasms 4 Glioblastoma 4 Colorectal Neoplasms 4 Breast Neoplasms 4 Stomach Neoplasms 3 Osteosarcoma 3 Non-Muscle Invasive Bladder Neoplasms 3 Neuroectodermal Tumors, Primitive 3 Myelodysplastic Syndromes 3 Lymphoma, Large B-Cell, Diffuse 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Squamous Cell 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Polycythemia Vera 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Desmoid Tumors × 1 year × Clear all

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡